Pathogenesis of Paradoxical Alopecia Areata During Dupilumab Therapy: What Is Known and Unknown

Dupilumab, a medication that blocks Th2-mediated cytokine signaling, has shown mixed results in treating alopecia areata (AA), an immune-mediated hair loss condition. In a study of 39 patients with both atopic dermatitis and AA, 61.5% improved with dupilumab, while 38.5% experienced worsening or new-onset AA. Higher baseline IgE levels were associated with better responses to dupilumab. Two theories explain these outcomes: one suggests that dupilumab may exacerbate AA by enhancing Th1 dominance, while the other proposes that it improves AA by normalizing regulatory T cell function. Further research is needed to understand the cytokine pathways involved in AA and the role of IgE levels in treatment response.